Screener
AnaptysBio, Inc. ANAB Biopharma Company — Income Tax Expense Benefit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Biopharma | Royalty Management | Total |
|---|---|---|---|
| (Loss) income from operations | (52,811) | 18,174 | (34,637) |
| Interest income | 2,328 | 325 | 2,653 |
| Non-cash interest expense | — | (20,859) | (20,859) |
| Other expense, net | (1) | — | (1) |
| Total other income (expense), net | 2,327 | (20,534) | (18,207) |
| Loss before income taxes | (50,484) | (2,360) | (52,844) |
| Provision for income taxes | — | (40) | (40) |
| Segment net loss | (50,484) | (2,400) | (52,884) |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s biopharma company — income tax expense benefit?
- AnaptysBio, Inc. (ANAB) reported biopharma company — income tax expense benefit of $0 in Q1 2026.
- What does biopharma company — income tax expense benefit mean?
- This metric represents the total income tax provision or benefit recognized by the biopharma business segment during the reporting period. It reflects the impact of tax regulations on the segment's financial performance, including deferred tax assets and liabilities. For clinical-stage companies, this is often zero due to consistent operating losses.
Ask your AI about AnaptysBio, Inc.'s biopharma company — income tax expense benefit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude